(dailyRx News) To avoid potentially lethal complications, stem cell transplants had to use cells donated by relatives of the patient or perfectly matched donors. Not anymore. Researchers are expanding the possibilities.
Velcade (bortezomib) added to other preventive medications lowered the incidence of acute graft-versus-host-disease (GVHD) and impoved one-year overall survival in patients who received stem cell transplants from mismatched and unrelated donors.
Read more from RxWiki HERE.